%0 Journal Article
%A Betge, Johannes
%A Barat, Ana
%A Murphy, Verena
%A Hielscher, Thomas
%A Van Grieken, Nicole C
%A Belle, Sebastian
%A Zhan, Tianzuo
%A Härtel, Nicolai
%A Kripp, Melanie
%A Bacon, Orna
%A Cordes, Martijn
%A Kay, Elaine W
%A Verheul, Henk M W
%A Neerincx, Maarten
%A Hennessy, Bryan
%A Hofheinz, Ralf D
%A Gaiser, Timo
%A Ylstra, Bauke
%A Prehn, Jochen H M
%A Lambrechts, Diether
%A Byrne, Annette T
%A Ebert, Matthias P
%A Schulte, Nadine
%T Outcome of Colorectal Cancer Patients Treated with Combination Bevacizumab Therapy: A Pooled Retrospective Analysis of Three European Cohorts from the Angiopredict Initiative.
%J Digestion
%V 94
%N 3
%@ 1421-9867
%C Basel
%I Karger
%M DKFZ-2017-01635
%P 129 - 137
%D 2016
%X This study is aimed at analyzing the survival rates and prognostic factors of stage IV colorectal cancer patients from 3 European cohorts undergoing combination chemotherapy with bevacizumab.Progression free-survival (PFS) and overall survival (OS) were analyzed in 172 patients using the Kaplan-Meier method and uni- and multivariable Cox proportional hazards regression models.The median PFS was 9.7 and the median OS 27.4 months. Patients treated at centers in Germany (n = 97), Ireland (n = 32), and The Netherlands (n = 43) showed a median PFS of 9.9, 9.2, and 9.7 months, OS of 34.0, 20.5, and 25.1 months, respectively. Patients >65 years had a significantly shorter PFS (9.5 vs. 9.8 months) but not OS (27.4 vs. 27.5 months) than younger patients. High tumor grade (G3/4) was associated with a shorter PFS, T4 classification with both shorter PFS and OS. Fluoropyrimidine (FP) chemotherapy backbones (doublets and single) had comparable outcomes, while patients not receiving FP backbones had a shorter PFS. In multivariable analysis, age and non-FP backbone were associated with inferior PFS, T4 classification and therapy line >2nd were significantly associated with poor PFS and OS.The observed survival rates confirm previous studies and demonstrate reproducible benefits of combination bevacizumab regimens. Classification T4, non-FP chemotherapy backbone, and age >65 were associated with inferior outcome.
%K Angiogenesis Inhibitors (NLM Chemicals)
%K Pyrimidines (NLM Chemicals)
%K Bevacizumab (NLM Chemicals)
%K 5-fluoropyrimidine (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:27756074
%R 10.1159/000449412
%U https://inrepo02.dkfz.de/record/125509